Journal of Clinical Endocrinology & Metabolism, Vol 76, 494-498, Copyright © 1993 by Endocrine Society

ARTICLES

Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays

CA Spencer, D Schwarzbein, RB Guttler, JS LoPresti and JT Nicoloff
Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033.

TRH stimulation tests (n = 1109) were performed on 1061 ambulatory and 43 hospitalized patients with varying thyroid status, using a TSH immunochemiluminometric assay with third and fourth generation sensitivity characteristics (functional sensitivity, 0.01 and 0.001 mU/L, respectively). TRH test results were analyzed as both absolute (stimulated minus basal TSH) and fold (stimulated/basal TSH) responses. The absolute TRH response varied 8-fold across the physiological TSH range, whereas the mean fold response remained almost constant (mean +/- SEM, 8.5 +/- 0.2). The fold response became progressively attenuated as basal TSH values declined below physiological levels, becoming essentially absent in clinically thyrotoxic patients with markedly depressed basal serum TSH levels (0.007 +/- 0.002 mU/L). Progressive attenuation also occurred at hypothyroid TSH levels; a markedly impaired fold response (2.5 +/- 0.4) was characteristic of primary hypothyroid patients with basal TSH values greater than 50 mU/L. In untreated central hypothyroid patients with near-normal basal TSH levels, the TRH fold response was impaired (1.7 +/- 0.2), whereas in T4- replaced central hypothyroid patients, fold responses were near normal (5.6 +/- 1.2). Neither nonthyroidal illness, age, or sex appeared to influence the pattern of fold TRH response in the populations evaluated. When using third and fourth generation TSH methodology, the TRH-stimulated TSH fold response is more diagnostically useful than the absolute TRH response. However, if patients have an intact hypothalamic- pituitary axis, there appears to be no diagnostic advantage gained by TRH testing over an accurately measured basal TSH value.

This article has been cited by other articles:

				A.-S. Balavoine, M. Ladsous, F.-L. Velayoudom, V. Vlaeminck, C. Cardot-Bauters, M. d'Herbomez, and J.-L. Wemeau Hypothyroidism in patients with pseudohypoparathyroidism type Ia: clinical evidence of resistance to TSH and TRH Eur. J. Endocrinol., October 1, 2008; 159(4): 431 - 437. [Abstract] [Full Text] [PDF]

				S. A.R. Doi, D. Issac, S. Abalkhail, M. M. Al-Qudhaiby, M. F. Hafez, and K. A. S. Al-Shoumer TRH Stimulation When Basal TSH is Within the Normal Range: Is There "Sub-Biochemical" Hypothyroidism? Clin. Med. Res., October 1, 2007; 5(3): 145 - 148. [Full Text] [PDF]

				S. Liu, K. M. Ogilvie, K. Klausing, M. A. Lawson, D. Jolley, D. Li, J. Bilakovics, B. Pascual, N. Hein, M. Urcan, et al. Mechanism of Selective Retinoid X Receptor Agonist-Induced Hypothyroidism in the Rat Endocrinology, August 1, 2002; 143(8): 2880 - 2885. [Abstract] [Full Text] [PDF]

				J. W. Chu and L. M. Crapo The Treatment of Subclinical Hypothyroidism Is Seldom Necessary J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4591 - 4599. [Full Text] [PDF]

				A C Al-Abadi Subclinical thyrotoxicosis Postgrad. Med. J., January 1, 2001; 77(903): 29 - 29. [Full Text]

				D. C. Bauer, M. C. Nevitt, B. Ettinger, and K. Stone Low Thyrotropin Levels Are Not Associated with Bone Loss in Older Women: A Prospective Study J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2931 - 2936. [Abstract] [Full Text] [PDF]